Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Coya Therapeutics, Inc. ( (COYA) ) is now available.
On August 29, 2025, Coya Therapeutics, Inc. received a $4.2 million milestone payment from Dr. Reddy’s Laboratories Ltd. following the FDA’s acceptance of its Investigational New Drug Application for a Phase 2 study on COYA 302 for ALS treatment. This payment marks a significant step in Coya’s strategic partnership with Dr. Reddy’s and highlights progress in their clinical development efforts, potentially impacting their market position and stakeholder interests.
The most recent analyst rating on (COYA) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Coya Therapeutics, Inc. stock, see the COYA Stock Forecast page.
Spark’s Take on COYA Stock
According to Spark, TipRanks’ AI Analyst, COYA is a Neutral.
Coya Therapeutics, Inc. has a mixed outlook. Strong clinical progress and financial stability from a debt-free balance sheet with cash reserves are significant positives. However, persistent profitability and cash flow challenges weigh heavily on the overall score. Technical indicators suggest moderate momentum, while valuation remains pressured by ongoing losses. The company’s strategic advancements and funding efforts are positive but need to translate into improved financial performance to enhance the stock’s appeal.
To see Spark’s full report on COYA stock, click here.
More about Coya Therapeutics, Inc.
Coya Therapeutics, Inc. operates in the biotechnology industry, focusing on developing treatments for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS).
Average Trading Volume: 69,637
Technical Sentiment Signal: Buy
See more data about COYA stock on TipRanks’ Stock Analysis page.